Jaguar Health plans mid-2027 NDA filing for crofelemer for MVID
JAGX•Jaguar Health plans to file an NDA for crofelemer for MVID in mid-2027. The company reported Q3 2026 total revenue of $2.3 million.
JAGX•Jaguar Health plans to file an NDA for crofelemer for MVID in mid-2027. The company reported Q3 2026 total revenue of $2.3 million.
Jaguar Health plans to file an NDA for crofelemer for MVID in mid-2027. The company reported total revenue of $2.3 million for the third quarter of 2026.